

Hope. And the Science of Healing.

Assessing Readiness for Downside Risk in OCM

Anne Marie F. Rainey, MSN RN CHC

Clearview Cancer Institute

- Private, community practice in North Alabama
 - Six full service locations
 - Three satellite locations
- 17 MDs, 18 APPs
- ~550 patients a day
- Services
 - Clinical trials
 - Diagnostic imaging
 - Genetic testing and counseling
 - Genomic testing
 - Lab services
 - Lung Cancer screening
 - Outpatient therapy
 - Radiation oncology
 - Specialty pharmacy
 - Stem Cell transplant
- OCM Team
 - 3 FTEs



Success to Date

- Project implementation
- Quality metrics
- Achieving PBP

Data Analysis

- Tools utilized
- Conditions in our favor
 - Success in reducing ED visits, increased in-office services
 - Coding
 - Other model coefficients
- Areas for improvement
 - Palliative care and hospice use
 - Continued reduction in IP admissions and ED visits
 - Pathway adherence
 - Formulary changes

Options and Considerations

Options

- Remain in one-sided risk
- Elect two-sided risk with risk partner
- Elect two-sided risk with stop-loss insurance

Considerations

- New practices added in Q3/Q4 2018
- Adding a new practice in December 2019 that is a current OCM practice
- Practice risk tolerance
- Final decision